Identification of a calcium binding site in the protease domain of human blood coagulation factor VII: evidence for its role in factor VII-tissue factor interaction.

Previous studies have identified a putative calcium binding site involving two glutamic acid residues located in the protease domain of coagulation factor IX. Amino acid sequence homology considerations suggest that factor VII (FVII) possesses a similar site involving glutamic acid residues 210 and 220. In the present study, we have constructed site-specific mutants of human factor VII in which Glu-220 has been replaced with either a lysine (E220K FVII) or an alanine (E220A FVII). These mutants were indistinguishable from wild-type factor VII by SDS-PAGE but only possessed 0.1% the coagulant activity of factor VII. Incubation of E220K/E220A FVII with factor Xa resulted in a slower than normal activation rate which eventually yielded a two-chain factor VIIa molecule possessing a coagulant activity of approximately 10% that of wild-type rFVIIa. Amidolytic activity measurements indicated that E220K/E220A FVIIa, unlike wild-type factor VIIa, possessed no measurable amidolytic activity toward the chromogenic substrate S-2288, even at high CaCl2 concentrations. Addition of tissue factor apoprotein, however, induced the amidolytic activity of the mutant molecule to a level 30% of that observed for wild-type factor VIIa. This tissue factor dependent enhancement of E220K/E220A FVIIa amidolytic activity was calcium dependent and required a CaCl2 concentration in excess of 5 mM for maximal rate enhancement. This was in sharp contrast to wild-type factor VIIa which required CaCl2 levels of 0.5 mM for maximal enhancement of tissue factor dependent amidolytic activity. Competition binding experiments suggest that the decrease in amidolytic and coagulant activity observed in the factor VII mutants is a direct result of impaired tissue factor binding.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  L. Petersen,et al.  Two different Ca2+ ion binding sites in factor VIIa and in des(1–38) factor VIIa , 1992, FEBS letters.

[2]  W. Kisiel,et al.  The Role of Phospholipids and the Factor VII Gla-Domain in the Interaction of Factor VII with Tissue Factor , 1992, Thrombosis and Haemostasis.

[3]  J. Birktoft,et al.  Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  W. Kisiel,et al.  Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. , 1991, Biochemistry.

[5]  G. Miller,et al.  Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male. , 1991, Blood.

[6]  W. Kisiel,et al.  Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine. , 1991, The Journal of biological chemistry.

[7]  W. Kisiel,et al.  Inhibition of Recombinant Human Blood Coagulation Factor VIIa Amidolytic and Proteolytic Activity by Zinc Ions , 1991, Thrombosis and Haemostasis.

[8]  K. Norris,et al.  Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. , 1990, The Journal of biological chemistry.

[9]  W. Kisiel,et al.  The importance of residues 195-206 of human blood clotting factor VII in the interaction of factor VII with tissue factor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. Boel,et al.  Quenching of the amidolytic activity of one-chain tissue-type plasminogen activator by mutation of lysine-416. , 1990, Biochemistry.

[11]  W. Kisiel,et al.  Synthesis, purification, and characterization of an Arg152----Glu site-directed mutant of recombinant human blood clotting factor VII. , 1990, Biochemistry.

[12]  W. Kisiel,et al.  The gamma-carboxyglutamic acid domain of human factor VIIa is essential for its interaction with cell surface tissue factor. , 1990, The Journal of biological chemistry.

[13]  I. Campbell,et al.  The first EGF‐like domain from human factor IX contains a high‐affinity calcium binding site. , 1990, The EMBO journal.

[14]  L. Pedersen,et al.  Calcium ion binding to human and bovine factor X. , 1990, Blood Coagulation and Fibrinolysis.

[15]  L. Petersen,et al.  Autoactivation of human recombinant coagulation factor VII. , 1989, Biochemistry.

[16]  R Shapiro,et al.  Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. , 1989, Biochemistry.

[17]  J. Laurence,et al.  Effect of Glucocorticoids on Chronic Human Immunodeficiency Virus (HIV) Infection and HIV Promoter-Mediated Transcription , 1989 .

[18]  W. Kisiel,et al.  Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells. , 1989, Blood.

[19]  David J Weber,et al.  Phospholipid binding properties of bovine prothrombin peptide residues 1-45. , 1988, Journal of Biological Chemistry.

[20]  L. Thim,et al.  Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. , 1988, Biochemistry.

[21]  W. Kisiel,et al.  Evidence that plasma lipoproteins inhibit the factor VIIa-tissue factor complex by a different mechanism that extrinsic pathway inhibitor. , 1987, Blood.

[22]  A. Guha,et al.  Affinity purification of human tissue factor: interaction of factor VII and tissue factor in detergent micelles. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Rapaport,et al.  A monoclonal antibody to factor IX that inhibits the factor VIII:Ca potentiation of factor X activation. , 1985, The Journal of biological chemistry.

[24]  W. Kisiel,et al.  A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin. , 1984, The Journal of clinical investigation.

[25]  A. Holmgren,et al.  Calcium-binding properties of bovine factor X lacking the gamma-carboxyglutamic acid-containing region. , 1984, Journal of Biological Chemistry.

[26]  D. Masys,et al.  Activation Of Human Factor VII By Activated Factors IX And X In Purified Systems , 1982, Thrombosis and Haemostasis.

[27]  S. Bajaj.  Cooperative Ca2+ binding to human factor IX. Effects of Ca2+ on the kinetic parameters of the activation of factor IX by factor XIa. , 1982, The Journal of biological chemistry.

[28]  S. Rapaport,et al.  Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. , 1981, The Journal of biological chemistry.

[29]  P. Majerus,et al.  [19] Human factor VII , 1981 .

[30]  R. Martin,et al.  Terbium luminescence as a probe of the calcium binding site of trypsin and α-chymotrypsin , 1980 .

[31]  R. Martin,et al.  Lanthanide probes in biological systems: the calcium binding site of pancreatic elastase as studied by terbium luminescence. , 1980, Biochemistry.

[32]  P. Majerus,et al.  Purification and properties of human coagulation factor VII. , 1980, The Journal of biological chemistry.

[33]  K. Fujikawa,et al.  Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). , 1977, Biochemistry.

[34]  J. Reuben,et al.  Calcium binding site of trypsin as probed by lanthanides. , 1977, Biochemistry.

[35]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.

[36]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.